- Maropitant citrate
1st Int Conf Drug Des Disc (February 4-7, Dubai) 2008, Abst P-140
WHO Drug Inf 2004, 18(1): 56
13th World Congr Pain (August 29-September 2, Montreal) 2010, Abst PW 320
9th Int ISSX Meet (September 4-8, Istanbul) 2010, Abst P343
Annu Meet Am Soc Anesthesiol (ASA) (October 15-19, Chicago) 2011, Abst A1585
|US8183230||5-23-2012||Antimicrobial preservatives to achieve multi-dose formulation using beta-cyclodextrins for liquid dosage forms|
|US2009099364||4-17-2009||Process for preparation of 1-(2s,3s)-2-benzhydryl-n-(5- tert-butyl-2-methoxybenzyl)quinuclidin-3-amine|
|US2007155782||7-6-2007||Nk-1 receptor antagonists anesthesia recovery|
|US2007129328||6-8-2007||Pharmaceutical compositions of neurokinin receptor antagonists and cyclodextrin and methods for improved injection site toleration|
|US2003139443||7-25-2003||Use of tachykinin antagonists, including NK-1 receptor antagonists, to modify unwanted behavior in dogs, cats and horses|
|US6255320||7-4-2001||Polymorphs of a crystalline azo-bicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions|
|US5990125||11-24-1999||NK-1 receptor antagonists for the treatment of cancer|
|EP0790825||8-28-1997||NK-1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF EYE DISORDERS|
|WO9713514||4-18-1997||NK-1 RECEPTOR ANTAGONISTS FOR PREVENTION OF NEUROGENIC INFLAMMATION IN GENE THERAPY|
|US5576317||11-20-1996||NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of|
|WO9614845||5-24-1996||NK-1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF EYE DISORDERS|
|US5519033||5-22-1996||Azabicyclo derivatives for treatment of urinary incontinence|
|US5393762||2-29-1995||Pharmaceutical agents for treatment of emesis|
|US5340826||8-24-1994||Pharmaceutical agents for treatment of urinary incontinence|
U.S. Pat. No. 5,393,762 and U.S. Ser. No. 08/816,016, both incorporated by reference, describe pharmaceutical compositions and treatment of emesis using NK-1 receptor antagonists. The citrate monohydrate has significantly enhanced stability over other salt forms such as the benzoate which was unstable even at 5° C. The mesylate form is deliquescent.
The compound of Formula I also improves anesthesia recovery in mammals. A co-pending U.S. provisional application No. 60/540,697 assigned to and owned by Pfizer Inc., describes a method of improving anesthesia recovery by administering a NK-1 antagonist prior to, during or after the administration of general anesthesia.
Preparation of (2S,3S)-2-benzhydryl-N-(5-tert-butyl-2-methoxybenzyl) quinuclidin-3-amine citrate monohydrate, Compound of Formula Ia Step C, Scheme II
A solution of (2S,3S)-2-benzhydryl-N-(tert-butyl-2-methoxybenzyl) quinuclidin-3-amine (33.95 kg, 72.4 moles) and anhydrous citric acid (15.3 kg, 79.7 moles) in a mixture of acetone (215 kg) and water (13.6 kg) was heated to 38-42° C. The resultant mixture was then transferred to another reactor via an in-line filter. The transfer line and filter were washed through with acetone (54 kg) and these filtered washings were added to the solution. The resultant mixture was then cooled to 20-25° C. and filtered fart-butyl methyl ether (252 kg) was added portion-wise over a period of approximately 35 minutes. The resultant suspension was then granulated at 20-25° C. for approximately 20 hours. The solid was then collected by filtration on an agitated filter-dryer and the filter cake was washed twice with filtered tert-butyl methyl ether (50 kg each). The resultant solid was then dried at 35° C. under vacuum with agitation to give the title compound (44.4 kg) as a colourless solid. The product was then milted.
1H-NMR (500 MHz, d6-methanol, 30° C.) δ: 7.46 (2H, d), 7.45 (2H, d), 7.37 (4H, m), 7.31 (1H, m), 7.29 (1H, m), 7.24 (1H, dd), 6.95 (1H, d), 6.76 (1H, d), 4.75 (1H, dd), 4.71 (1H, d), 3.76 (1H, m), 3.57 (1H, d), 3.55 (3H, s), 3.37 (1H, m), 3.31 (1H, m), 3.26 (1H, m), 3.24 (1H, d), 3.10 (1H, t), 2.83 (2H, d), 2.75 (2H, d), 2.51 (1H, m), 2.35 (1H, m), 2.11 (1H, m), 2.06 (1H, m), 1.85 (1H, m), 1.29 (9H, s).
13C NMR (125.7 MHz, d6-methanol, 30° C.) δ: 179.4, 175.0, 156.8, 144.0, 141.5, 141.4, 131.1, 130.6, 129.4, 128.9, 128.7, 128.3, 128.2, 127.2, 126.4, 111.0, 74.0, 64.7, 56.1, 54.2, 50.4, 48.5, 48.3, 44.9, 43.8, 34.8, 32.9, 25.3, 22.2, 18.1.
LRMS (ES+): m/z [MH+] 469.
DR ANTHONY MELVIN CRASTO Ph.D